To evaluate the cost-utility of eculizumab versus supportive therapy in the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
From the perspective of whole Chinese society, a partitioned survival model was constructed to simulate the total cost, quality-adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) of patients over a lifetime (40 years) with a discount rate of 5%. One-way sensitivity analysis and probabilistic sensitivity analysis were used to verify the robustness of the model.
The base-case results showed that compared with supportive therapy, patients who used eculizumab could obtaine 8.50 more QALYs and an incremental cost of 639 784 CNY, the ICER was 75 297 CNY/QALY, which was lower than the GDP per capita in 2023. The one-way sensitivity analysis showed that the annual spontaneous remission rate had the most significant impact on the final result. The probabilistic sensitivity analysis showed that the probability of cost-effective of eculizumab was 99.98% when the willingness-to-pay threshold was 3 times of GDP per capital.
From the perspective of the Chinese society, eculizumab was a cost-effective treatment regimen compared to supportive therapy in the treatment of PNH patients.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |